Holen Sie sich die Stockscreener-App
3.25
1.52%
-0.04
Schlusskurs vom Vortag:
$3.29
Offen:
$3.3
24-Stunden-Volumen:
240.39K
Relative Volume:
0.20
Marktkapitalisierung:
$475.01M
Einnahmen:
$185.74M
Nettoeinkommen (Verlust:
$-230.76M
KGV:
-3.5876
EPS:
-0.9059
Netto-Cashflow:
$-70.72M
1W Leistung:
-8.73%
1M Leistung:
+9.46%
6M Leistung:
+21.35%
1J Leistung:
+33.88%
1-Tages-Spanne:
$3.23
$3.37
1-Wochen-Bereich:
$3.23
$3.835
52-Wochen-Spanne:
$1.665
$4.105
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Firmenname
Maravai Lifesciences Holdings Inc
Sektor
Branche
Telefon
(858) 546-0004
Adresse
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
3.245 | 481.60M | 185.74M | -230.76M | -70.72M | -0.9059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.37 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.22 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.32 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.61 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.49 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-12-19 | Eingeleitet | Guggenheim | Neutral |
| 2024-12-05 | Herabstufung | Goldman | Neutral → Sell |
| 2024-11-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-04-10 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-08-08 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-01-05 | Herabstufung | UBS | Buy → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-11-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-12-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-15 | Eingeleitet | Credit Suisse | Outperform |
| 2020-12-15 | Eingeleitet | Goldman | Buy |
| 2020-12-15 | Eingeleitet | Jefferies | Buy |
| 2020-12-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-12-15 | Eingeleitet | Stifel | Buy |
| 2020-12-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-14 | Eingeleitet | UBS | Buy |
Alle ansehen
Maravai Lifesciences Holdings Inc Aktie (MRVI) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Investors to Inquire about Securities Investigation - ACCESS Newswire
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Maravai LifeSciences Holdings, Inc. (MRVI) And Encourages Stockholders to Reach Out - ACCESS Newswire
How rising interest rates impact Maravai LifeSciences Holdings Inc. stockEntry Point & Precise Trade Entry Recommendations - Naître et grandir
How does Maravai LifeSciences Holdings Inc score in quality rankings2025 Big Picture & Fast Momentum Entry Tips - baoquankhu1.vn
Targets Report: What are Maravai LifeSciences Holdings Incs earnings expectations2025 Price Targets & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Maravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI) - MarketBeat
Royce & Associates LP Has $5.06 Million Stock Position in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
First Eagle Investment Management LLC Makes New Investment in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
MRVI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Maravai Lifesciences Charts Early Turnaround in 2025 - TipRanks
Maravai LifeSciences (NASDAQ:MRVI) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Assessing a Potential 14% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives - simplywall.st
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap UpStill a Buy? - MarketBeat
Is Maravai LifeSciences Holdings Inc.’s ROE strong enoughMarket Growth Report & Fast Exit and Entry Trade Guides - mfd.ru
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts - Investing.com Nigeria
Maravai LifeSciences Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call Highlights: Surpassing Revenue ... By GuruFocus - Investing.com Canada
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Maravai LifeSciences Q4 Earnings Call Highlights - MarketBeat
Maravai LifeSciences Holdings, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:MRVI) 2026-02-26 - Seeking Alpha
Maravai LifeSciences Holdings Inc (MRVI) Q4 2025 Earnings Call H - GuruFocus
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Maravai Q4 2025 slides: return to positive EBITDA on cost cuts By Investing.com - Investing.com South Africa
Earnings call transcript: Maravai Lifesciences Q4 2025 beats EPS forecast, stock jumps 4.5% - Investing.com Canada
MRVI: 2025 saw revenue beat, margin recovery, and strong 2026 growth and profitability guidance - TradingView
Maravai LifeSciences Holdings Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Maravai LifeSciences (NASDAQ:MRVI) Issues Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Maravai LifeSciences Holdings, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
MRVI Projects FY26 Adjusted EBITDA Between $18M and $20M - GuruFocus
Maravai LifeSciences (MRVI) Surpasses Revenue Expectations in Q4 - GuruFocus
Maravai LifeSciences (NASDAQ: MRVI) posts 2025 loss but targets 2026 EBITDA rebound - Stock Titan
Maravai LifeSciences Q4 2025 Earnings Call Transcript - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Maravai LifeSciences Holdings, Inc. (MRVI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Maravai LifeSciences Holdings, Inc. (MRVI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
What are Maravai LifeSciences Holdings Inc.’s growth levers2025 Geopolitical Influence & Weekly High Return Stock Opportunities - mfd.ru
Maravai LifeSciences Holdings, Inc. $MRVI Shares Bought by Monaco Asset Management SAM - MarketBeat
Value Recap: What is the PEG ratio of Maravai LifeSciences Holdings IncEarnings Overview Report & Daily Entry Point Alerts - baoquankhu1.vn
Maravai LifeSciences Holdings (MRVI) Investor Outlook: Navigating a 27.55% Upside Amidst Challenging Metrics - DirectorsTalk Interviews
Maravai LifeSciences Holdings, Inc. (MRVI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Stock Traders Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI) - MarketBeat
Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
12 West Capital (NASDAQ: MRVI) discloses 6.2% beneficial stake in Maravai - Stock Titan
Is There An Opportunity With Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 34% Undervaluation? - Yahoo Finance
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of "Hold" by Brokerages - MarketBeat
MRVI Should I Buy - Intellectia AI
Market Moves: Will REFI face regulatory challengesWeekly Investment Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Investor group (NASDAQ: MRVI) reports 7.23% Maravai LifeSciences stake - Stock Titan
Options Flow: Will Cohen Company Inc face regulatory challengesQuarterly Trade Review & Smart Investment Allocation Tips - baoquankhu1.vn
Finanzdaten der Maravai Lifesciences Holdings Inc-Aktie (MRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):